Rankings / Sleep & Recovery

Curcumin (turmeric)

Sleep & Recovery · Polyphenol

Tier C+

Reviewed by Read Off Label · Last reviewed · How we grade

polyphenolantioxidantcox-pathwayhepatotoxicity-flagnafldotc
5.5 / 10
Tier C+
Ev 6 Bn 5 Sf 5

Bottom line

Read Off Label grades Curcumin (turmeric) as C+ (5.5/10) based on moderate evidence, med benefit magnitude, and a med-risk safety profile.

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted.

Studied, labeled, or reported-use context: 500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine… — OTC; not individualized guidance.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Reverses on stopping

Reversible. Poor absorption limits systemic exposure in the first place.

Can you tell if it worked?

Readable — 8–12 weeks

Joint pain or stiffness scored daily; hs-CRP on a blood panel if inflammation is the target.

What would fool you Bioavailability differs by an order of magnitude between formulations, so this tests a product rather than the molecule. Joint pain fluctuates seasonally and with activity, and hs-CRP moves with any recent infection.

What the evidence says

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted. **The formulation paradox is the central biohacker decision input**: bioavailability-enhanced forms (Meriva/phytosome; Theracurmin; BCM-95; NovaSol; piperine-boosted) deliver 5-30x higher plasma curcumin, but hepatotoxicity case reports are CONCENTRATED in exactly these formulations. EFSA, Italian Phytovigilance, DILIN, and Icelandic case clusters all point the same direction — bioavailability-enhanced products at standard supplement doses produce occasional idiosyncratic cholestatic hepatitis. EFSA's 180 mg/day ADI is below typical biohacker dosing. Italian Ministry of Health required new warning labels on Curcuma longa supplements 2024-2025. **OA paradox**: 2025 network MA on knee OA (17 studies) found conventional curcuminoid preparations had numerically LARGER WOMAC pain reduction (-3.17) than bioavailability-enhanced ones (-2.47) — complicates the "phytosomal is better" supplement-industry narrative. NAFLD/MASLD is the strongest specific indication for phytosomal curcumin per the 2025 ALT/AST pooled MA. **Evidence summary for 2024-2025**: conventional curcuminoids showed numerically larger OA estimates than enhanced formulations in the cited network meta-analysis; the EFSA ADI is about 3 mg/kg/day; enhanced-bioavailability formulations are overrepresented in hepatotoxicity reports; and LFT abnormalities, jaundice, dark urine, or right-upper-quadrant pain are clinical hepatotoxicity signals. NAFLD trials include phytosomal formulations under monitoring; the cited OA network meta-analysis produced numerically larger estimates for conventional formulations.

Mechanism

Diferuloylmethane polyphenol from Curcuma longa; pleiotropic effects — NF-κB; COX-2; 5-LOX; JAK-STAT; Nrf2 inhibition/activation across dozens of pathways; native curcumin has <1% oral bioavailability and is rapidly conjugated/excreted; formulation strategies (phytosome, micelle, nanoemulsion, piperine co-administration) raise plasma exposure 5-30x

Studied, labeled, or reported dose & route

500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine 5-20 mg co-admin (~20x); phytosome/Meriva (~20-29x AUC); BCM-95 (~7x); Theracurmin (~27x AUC and ~5.6x Cmax vs Meriva); NovaSol micelle (very high Cmax with rapid decline)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Curcumin (turmeric)'s effects?
Read Off Label rates the evidence for Curcumin (turmeric) as Moderate and the benefit magnitude as med, producing an overall grade of C+ (5.5/10). Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted.
What safety findings are reported for Curcumin (turmeric)?
Curcumin (turmeric) has a med risk profile in the database. Med (the formulation paradox — hepatotoxicity case reports are concentrated in HIGH-bioavailability formulations: Italian Phytovigilance / Tuscany cluster, DILIN 10-case US series, Icelandic case reports — most linked to Meriva/phytosome or piperine-boosted products at standard supplement doses; rare idiosyncratic non-infectious cholestatic hepatitis; iron chelation potential; theoretical anticoagulant interactions) Legal status: OTC (EFSA ADI 180 mg curcumin/day for 60 kg adult ≈ 3 mg/kg/day; Italian Ministry of Health required new hepatotoxicity warning labels 2024-2025).
What doses or routes are reported for Curcumin (turmeric)?
500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine 5-20 mg co-admin (~20x); phytosome/Meriva (~20-29x AUC); BCM-95 (~7x); Theracurmin (~27x AUC and ~5.6x Cmax vs Meriva); NovaSol micelle (very high Cmax with rapid decline) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Curcumin (turmeric) work?
Diferuloylmethane polyphenol from Curcuma longa; pleiotropic effects — NF-κB; COX-2; 5-LOX; JAK-STAT; Nrf2 inhibition/activation across dozens of pathways; native curcumin has <1% oral bioavailability and is rapidly conjugated/excreted; formulation strategies (phytosome, micelle, nanoemulsion, piperine co-administration) raise plasma exposure 5-30x

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.